Loading clinical trials...
Loading clinical trials...
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in Individuals With Impaired and Normal Glucose Tolerance
Conditions
Interventions
Dorzagliatin
Placebo
Start Date
August 1, 2022
Primary Completion Date
April 1, 2023
Completion Date
April 1, 2023
Last Updated
July 25, 2022
NCT04737200
NCT05468255
NCT03681054
NCT05050500
NCT01839448
NCT07194772
Lead Sponsor
Chinese University of Hong Kong
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions